Zurcher Kantonalbank Zurich Cantonalbank Sells 2,268 Shares of UiPath Inc. (NYSE:PATH)

Zurcher Kantonalbank Zurich Cantonalbank reduced its holdings in UiPath Inc. (NYSE:PATH) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,231 shares of the healthcare company’s stock after selling 2,268 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in UiPath were worth $2,291,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Royal London Asset Management Ltd. increased its stake in UiPath by 5.9% during the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock worth $2,388,000 after purchasing an additional 7,742 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new position in shares of UiPath in the third quarter valued at approximately $203,000. Invesco Ltd. increased its position in shares of UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after acquiring an additional 10,863 shares in the last quarter. Symmetry Partners LLC bought a new stake in shares of UiPath during the fourth quarter worth $205,000. Finally, Toroso Investments LLC raised its holdings in shares of UiPath by 196.7% during the third quarter. Toroso Investments LLC now owns 78,189 shares of the healthcare company’s stock worth $1,338,000 after acquiring an additional 51,834 shares during the period. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Price Performance

Shares of NYSE PATH opened at $19.54 on Wednesday. The business’s 50 day moving average price is $22.55 and its two-hundred day moving average price is $21.56. UiPath Inc. has a twelve month low of $12.38 and a twelve month high of $27.87.

UiPath (NYSE:PATH) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. As a group, equities research analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PATH has been the subject of a number of research analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $32.00 target price on shares of UiPath in a research note on Wednesday, March 20th. William Blair assumed coverage on UiPath in a report on Tuesday, January 2nd. They set an “outperform” rating for the company. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. DA Davidson upped their price target on UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Finally, Barclays lifted their price objective on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, March 15th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.41.

Insider Transactions at UiPath

In related news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total value of $866,400.00. Following the transaction, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 72,000 shares of company stock worth $1,591,360. 31.03% of the stock is owned by insiders.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.